Stocks On the Move: Biogen Inc, AveXis Inc, and Amphastar Pharmaceuticals Inc

Biotech stocks Biogen Inc (BIIB), AveXis Inc (AVXS), and Amphastar Pharmaceuticals Inc (AMPH) are among the stocks making big moves in today's trading

Dec 27, 2016 at 2:45 PM
facebook X logo linkedin


U.S. stocks are higher, as tech stocks and homebuilders lead. Among specific equities in focus today are biotech stocks Biogen Inc (NASDAQ:BIIB), AveXis Inc (NASDAQ:AVXS), and Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Here's a quick look at what's moving BIIB, AVXS, and AMPH.

  • BIIB is up 1.4% at $291.42, after the U.S. Food and Drug Administration (FDA) granted approval for its spinal muscular atrophy drug, nusinersen, developed in partnership with Ionis Pharmaceuticals Inc (NASDAQ:IONS). BIIB is up more than 30% since its late-June lows, though the shares still sit below the key $300 level. Option bulls have been betting on more upside, with Biogen Inc's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 2.20 sitting in the 84th percentile of its annual range.

  • AVXS is down 6.4% at $49.90, after BIIB's FDA approval. AveXis Inc is currently developing a similar drug, AVXS-101, which would now be the second spinal muscular atrophy drug available on the market, if approved. However, one Chardan analyst thinks AVXS-101 could still clear space in the market, given its lower death rate, which gives it the potential to be a "breakthrough therapy." The Wall Street rookie has tumbled nearly 32% since hitting an all-time peak last month, and short sellers have been piling on. Short interest on AVXS surged 171.95% during the past two reporting periods, and now accounts for 20% of the stock's total available float.
  • AMPH is among the worst performers on the Nasdaq, currently trading 9.2% lower at $18.56, on news that the FDA has issued a Complete Response Letter (CRL) denying the biotech's New Drug Application (NDA) (subscription required) for its primatene mist asthma inhaler. Amphastar Pharmaceuticals Inc's CEO said the company will work to address the FDA's concerns by the middle of 2017. AMPH is still up more than 75% since its early March lows, though the shares now sit below the $19.50 level that has acted as support since a mid-November bull gap. Short sellers are likely cheering today's move, with AMPH's 2.7 million shorted shares accounting for more than 7.4% of AMPH's float, which would take just under two weeks of trading to cover, at the stocks' average daily volume.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI